Shanghai Pharma IPO prices in the middle
Shanghai Pharmaceutical priced its Hong Kong IPO near the middle of its price range last week, raising HK$15.3bn ($1.97bn) from the secondary listing.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts